Contract Pharma

CONTRACT PHARMA stands out as the sole global publication dedicated to Bio/Pharma contract services, boasting a verified circulation of 20,026. This publication offers more in-depth editorial content on contract services and outsourcing than any other source. In 2013 alone, we featured over 700 pages of editorial content centered on outsourcing across our nine issues. CONTRACT PHARMA holds the top position in advertising market share for contract services and outsourcing providers within the Pharma and Biopharma sectors.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#582903

United States

#335607

Health/Biotechnology and Pharmaceuticals

#321

Traffic sources

Monthly visitors

Articles

Staying Ahead of DSCSA Enforcement in the Pharmaceutical Supply Chain

4 weeks ago | contractpharma.com | Tim Wright

The Drug Supply Chain Security Act (DSCSA), established in 2013, set a foundation for tracking and verifying pharmaceutical products across the United States. However, while the regulations have been phased in for over a decade, its regulatory requirements continue to evolve, introducing new challenges for the industry.
Safety Meets Accessibility: Creating the Ideal Packaging for On-The-Go Dosage Forms

4 weeks ago | contractpharma.com | Tim Wright

Patient-centric innovation is reshaping our industry, with its influence extending beyond formulations to encompass thoughtful packaging design. This holistic approach aligns with evolving consumer expectations—today’s patients demand medications and supplements that are not only effective and safe, but also convenient and quick to use.
Fill-Finish Outsourcing

4 weeks ago | contractpharma.com | Tim Wright

The fill-finish stage of pharmaceutical manufacturing may not make headlines, but it is the final crucial step—the point where all the work behind a new drug either comes together or falls apart due to contamination, inefficiencies, or regulatory setbacks. Right now, the demand for high-quality, adaptable fill-finish services is soaring.
Pharmaceutical Manufacturing Equipment Trends

1 month ago | contractpharma.com | Kristin Brooks

Significant growth in demand for pharmaceuticals, such as GLP-1s, increased R&D spending for autonomous manufacturing, and the increased presence of contract manufacturers globally are among the key factors attributing to growth in the pharmaceutical manufacturing equipment market.
Fill‐Finish Outsourcing Trends

1 month ago | contractpharma.com | Tim Wright

In today’s evolving pharmaceutical environment, the fill‐finish segment stands out as a critical linchpin connecting drug development with successful patient delivery. Driven by seismic shifts in global health trends, an evolving therapeutic landscape, and breakthroughs in manufacturing technology, fill‐finish outsourcing is undergoing a transformation unlike any seen before.
Closing the Gaps: Cybersecurity and Compliance Challenges in Pharma CDMOs

2 months ago | contractpharma.com | Tim Wright

In the pharmaceutical sector, contract development and manufacturing organizations (CDMOs) play a vital role in advancing healthcare by facilitating drug research, development, and production. However, managing extensive sensitive information comes with unique cybersecurity and compliance challenges. The threat landscape is increasingly perilous, with data breaches on the rise and stringent regulatory demands that CDMOs must meet to safeguard intellectual property and comply with global standards.
Improving Clinical Trial Enrollment and Retention

2 months ago | contractpharma.com | Tim Wright

Recent surveys suggest that as many as one-fifth to one-third of participants drop out of clinical studies.1,2 Certainly, precarious patient health is a contributing factor to such poor retention, as is misalignment on inclusion criteria. But those aren’t the only barriers to patient retention. Quite simply, too many patients find it too difficult to participate in clinical trials. As healthcare technologists, we assume a heavy responsibility for making clinical trial participation less burdensome.
Reimagining Continuous Manufacturing for Biologics: Beyond Perfusion to a Fully Connected Process

2 months ago | contractpharma.com | Tim Wright

Continuous manufacturing (CM) has become a contentious topic in the modern pharmaceutical lexicon, driven by divergent definitions—from perfusion and flow chemistry to fully integrated systems. In biologics production, CM is an emerging technology aimed at improving yields, reducing costs, and streamlining production processes. However, despite its recent media attention, misconceptions remain about what constitutes true continuous manufacturing in biologics production.
Addressing the Pain Points of Making Drug-Device Combination Products

2 months ago | contractpharma.com | Tim Wright

The launch of HUMIRA (adalimumab) as a single-dose prefilled syringe (PFS) in 2003 marked the start of a revolution in the delivery of vial-based biological products.
Unlocking the Potential of Value-Added Medicines

2 months ago | contractpharma.com | Tim Wright

Intensifying competition and pricing pressures in the pharmaceutical industry are placing demand on developers and manufacturers to explore innovative pathways to differentiate their products and create value, particularly in the generic drug market. As a result, many pharma companies are turning their focus to value-added medicines (VAMs) to achieve differentiation.